You Trusted a Stranger’s Netflix Password… But Not This?
Let’s not pretend you don’t take risks.
You’ve shared your location with a date you barely knew, let your cousin cut your hair to “save money.” Tried a mystery flavor energy drink from the back of a gas station, and maybe watched an entire true crime doc in the dark, alone, and then slept with the lights on.
But when it comes to putting $500 toward a real shot at saving lives and potentially earning a return on that bet? You’re hesitating?
What If the Smartest Risk Is the One You Can Explain to Your Mom?
Let’s make this super simple.
Worst case: You invest the same amount you spent on last month’s brunches and it doesn’t work out. It stings. But you move on.
Best case: You backed a breakthrough med-tech device that could…
- Catch life-threatening heart problems before they get scary
- Save families ER visits, anxiety, and regret
- Earn you a real return if they’re acquired like others in this space
This isn’t a fantasy startup. This is Future Cardia:
- Already implanted in 39 patients
- Over 60,000 hours of real-world cardiac data
- FDA submission targeted for this year
- Backed by Stanford StartX and J&J’s JLABS
- Competing in a $65B+ market with only three major players
Not Just Heart Monitoring, It’s Risk Monitoring for Real Life
The device goes under the skin in a 2-minute procedure, and quietly monitors for signs of arrhythmia and heart failure; the kind that come and go before anyone knows to do something about it.
No wires, no recharging. No “Did I leave it on the dresser?” moments.
This is for:
- Your uncle who swears it’s “just stress”
- Your friend who gets dizzy but won’t go to the doctor
- Your future self who deserves better than waiting to see if it gets worse
You’ve Got Until June 18, That’s It
Future Cardia’s investment round closes June 18.
After that, the round ends or the valuation changes. Either way, you’ll miss it. You don’t need to know anything about biotech to know a good moment when you see it.
Because you’ve gambled on worse, and this one? Might be the first risk you’ll feel really good about taking.
*This product is not yet available for purchase and requires review and clearance before being marketed or sold. This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.